Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression

Qingqing Cheng,Jihan Huang,Ling Xu,Yunfei Li,Huafang Li,Yifeng Shen,Qingshan Zheng,Lujin Li

DOI: https://doi.org/10.1093/ijnp/pyz062

2019-11-27

Abstract:Abstract Objective Model-based meta-analysis was used to describe the time-course and dose-effect relationships of antidepressants and also simultaneously investigate the impact of various factors on drug efficacy. Methods This study is a reanalysis of a published network meta-analysis. Only placebo-controlled trials were included in this study. The change rate in depression rating scale scores from baseline was used as an efficacy indicator because a continuous variable is more likely to reflect subtle differences in efficacy between drugs. Results A total 230 studies containing 64 346 patients were included in the analysis. The results showed that the number of study sites (single or multi-center) and the type of setting (inpatient or noninpatient) are important factors affecting the efficacy of antidepressants. After deducting the placebo effect, the maximum pure drug efficacy value of inpatients was 18.4% higher than that of noninpatients, and maximum pure drug efficacy value of single-center trials was 10.2% higher than that of multi-central trials. Amitriptyline showed the highest drug efficacy. The remaining 18 antidepressants were comparable or had little difference. Within the approved dose range, no significant dose-response relationship was observed. However, the time-course relationship is obvious for all antidepressants. In terms of safety, with the exception of amitriptyline, the dropout rate due to adverse events of other drugs was not more than 10% higher than that of the placebo group. Conclusion The number of study sites and the type of setting are significant impact factors for the efficacy of antidepressants. Except for amitriptyline, the other 18 antidepressants have little difference in efficacy and safety.

pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology

What problem does this paper attempt to address?

The main problems that this paper attempts to solve include the following aspects:

1. **Describe the time - course and dose - effect relationship of antidepressants**: Through the modeling method, researchers hope to accurately describe the time - course (that is, the change of drug efficacy over time) and dose - effect relationship (that is, drug efficacy at different doses) of antidepressants in the treatment of acute adult major depressive disorder.

2. **Evaluate various factors affecting drug efficacy**: In addition to time and dose, researchers also hope to explore the influence of other factors (such as the number of study sites, inpatient or outpatient settings, etc.) on drug efficacy simultaneously through the modeling method. This helps to provide more comprehensive quantitative information to guide the current clinical practice guidelines for depression.

Specifically, researchers used the model - based meta - analysis (MBMA) method to re - analyze the existing network meta - analysis data. This method can more accurately describe the time - course and dose - effect relationship of drugs and can simultaneously investigate the influence of multiple factors on drug efficacy. Compared with traditional meta - analysis, MBMA can make full use of the efficacy data at each time point, thus providing more detailed and accurate results.

### Key Formulas

The formulas involved in the article are mainly used to describe parameter estimation in the model and the influence of covariates. Here are several key formulas:

1. **Maximum possible efficacy in the placebo group (E_max, placebo)**:
\[
E_{\text{max, placebo},i} = \frac{E_{\text{max, placebo},i}}{1 + e^{-\left(\frac{\text{Time}_m - ET_{50, \text{placebo},i}}{\eta_1}\right)}}
\]
where \( E_{\text{max, placebo},i} \) is the maximum possible efficacy in the placebo group in the \( i \) - th study, \( ET_{50, \text{placebo},i} \) is the time required to reach half of the maximum efficacy, and \( \eta_1 \) and \( \eta_2 \) are the between - study variabilities of \( E_{\text{max, placebo},i} \) and \( ET_{50, \text{placebo},i} \) respectively.

2. **Maximum possible pure drug efficacy in the drug group (E_max, drug)**:
\[
E_{\text{max, drug},i,j} = \frac{E_{\text{max, drug},i,j}}{1 + e^{-\left(\frac{\text{Time}_m - ET_{50, \text{drug},i,j}}{\eta_3}\right)}}
\]
where \( E_{\text{max, drug},i,j} \) is the maximum possible pure drug efficacy in the \( j \) - th drug group in the \( i \) - th study, \( ET_{50, \text{drug},i,j} \) is the time required to reach half of the maximum pure drug efficacy, and \( \eta_3 \) and \( \eta_4 \) are the between - study variabilities of \( E_{\text{max, drug},i,j} \) and \( ET_{50, \text{drug},i,j} \) respectively.

3. **Correction formula for the influence of covariates**:
\[
E_{\text{max, drug},i,\text{corrected}} = E_{\text{max, drug},i} - 18.4\times \text{Type}_i - 10.2\times \text{Center}_i
\]
where \( \text{Type}_i \) indicates whether it is an inpatient (1 for inpatient, 0 for outpatient), and \( \text{Center}_i \) (the description of this variable seems incomplete in the original text).